121TiPKEYNOTE-756: Randomized, double-blind, phase III...

121TiPKEYNOTE-756: Randomized, double-blind, phase III study of pembrolizumab vs placebo + neoadjuvant chemotherapy (CT) and adjuvant endocrine therapy (ET) for high-risk, early-stage estrogen receptor–positive human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer (BC)

Cardoso, F, Jia, L, Hirshfield, K, Karantza, V
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz097.013
Date:
May, 2019
File:
PDF, 76 KB
2019
Conversion to is in progress
Conversion to is failed